Skip to main content
. 2011 Jul;85(14):6832–6843. doi: 10.1128/JVI.00609-11

Fig. 5.

Fig. 5.

Vaccination with the chimeric rIBV-NS110-AHA protects BALB/c mice against lethal infection with influenza A virus. Eight-week-old female BALB/c mice (n = 10) were vaccinated with 10-fold serial dilutions of rIBV-NS110-PR8HA (A and C) or rIBV-NS110-HK68HA (B and D) (from 1 × 105 PFU to 1 × 102 PFU). Control groups were immunized with 1 × 105 PFU rWT B/Ya88 virus or mock treated with PBS. Three weeks postvaccination, for viral lung replication study the mice were infected with either 1 ×102 PFU of A/PR8 virus (n = 6) or 5 × 104 PFU of A/X31 virus (n = 6). For stringent viral survival studies, mice were infected with a higher dose of 1 × 103 PFU of A/PR8 virus (n = 4) or 1 ×106 PFU of A/X31 virus (n = 4). (A and B) The pulmonary replication of influenza A viruses in vaccinated mice on days 3 and 6 p.i. Average lung titers ± standard deviations are depicted. The limit of detection was 5 PFU. (C and D) Animals were monitored for body weight changes and survival for a total of 14 days postchallenge.